Diana R. Kerwin
Expertise in
7
conditions

Dr. Diana R. Kerwin

Geriatrics | Internal Medicine
8198 Walnut Hill Ln, Ste 100, 
Dallas, TX 
Accepting New Patients
Referral may be required
Before you request
Expertise in
7
conditions
8198 Walnut Hill Ln, Ste 100, 
Dallas, TX 

Overview

Diana Kerwin is a primary care provider, practicing in Geriatrics and Internal Medicine in Dallas, Texas.

Dr. Kerwin is highly rated in 7 conditions, according to our data. Her clinical expertise encompasses Dementia, Alzheimer's Disease, Frontotemporal Dementia, and Supranuclear Ophthalmoplegia.

She is actively involved in clinical research, co-authoring 39 peer reviewed articles and participating in 12 clinical trials. Dr. Kerwin is currently accepting new patients.

Specialties

Geriatrics
Internal Medicine

Licenses

Geriatric Medicine in WI

Fellowships

Northwestern University/Feinberg School of Medicine - Geriatric (2000)

Hospital Affiliations

Texas Health Dallas

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

Kerwin Research Center & Memory Care
8198 Walnut Hill Ln, Ste 100, Dallas, TX 75231

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: August 26, 2026
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled Platform Trial of Potential Disease Modifying Therapies Utilizing Biomarker, Cognitive, and Clinical Endpoints in Dominantly Inherited Alzheimer's Disease
A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled Platform Trial of Potential Disease Modifying Therapies Utilizing Biomarker, Cognitive, and Clinical Endpoints in Dominantly Inherited Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: July 27, 2026
Intervention Type: Drug
Study Drugs: Gantenerumab, Solanezumab
Study Phase: Phase 2/Phase 3
Assessment of Safety, Tolerability, and Efficacy of LY3372689 in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of LY3372689 in Early Symptomatic Alzheimer's Disease
Enrollment Status: Completed
Publish Date: June 12, 2026
Intervention Type: Drug
Study Drug: LY3372689
Study Phase: Phase 2
A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease
A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: January 21, 2026
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects With Mild to Moderate Alzheimer's Disease
A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects With Mild to Moderate Alzheimer's Disease
Enrollment Status: Completed
Publish Date: April 04, 2025
Intervention Type: Drug
Study Drug: ATH-1017
Study Phase: Phase 2/Phase 3
A Phase 3, Open-Label, Parallel-Group, 2-Arm Study to Investigate Amyloid Plaque Clearance With Donanemab Compared With Aducanumab-avwa in Participants With Early Symptomatic Alzheimer's Disease
A Phase 3, Open-Label, Parallel-Group, 2-Arm Study to Investigate Amyloid Plaque Clearance With Donanemab Compared With Aducanumab-avwa in Participants With Early Symptomatic Alzheimer's Disease
Enrollment Status: Completed
Publish Date: November 29, 2024
Intervention Type: Drug
Study Drugs: Donanemab, Aducanumab
Study Phase: Phase 3
GAIN Trial: A Randomized, Double-Blind, Placebo-Controlled Study of COR388 in Subjects With Alzheimer's Disease
GAIN Trial: A Randomized, Double-Blind, Placebo-Controlled Study of COR388 in Subjects With Alzheimer's Disease
Enrollment Status: Completed
Publish Date: February 23, 2023
Intervention Type: Drug
Study Drug: COR388
Study Phase: Phase 2/Phase 3
Development of a Biomarker Database to Investigate Aß, P-tau, and NfL Blood-Based Biomarkers and Digital Biomarkers in Older Participants Screened for Preclinical Alzheimer's Disease (AD), Prodromal AD, or Mild AD
Development of a Biomarker Database to Investigate Aß, P-tau, and NfL Blood-Based Biomarkers and Digital Biomarkers in Older Participants Screened for Preclinical Alzheimer's Disease (AD), Prodromal AD, or Mild AD
Enrollment Status: Completed
Publish Date: February 09, 2023
Intervention Type: Other
A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects With Early Alzheimer's Disease
A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects With Early Alzheimer's Disease
Enrollment Status: Completed
Publish Date: August 26, 2022
Intervention Type: Drug
Study Drug: Tilavonemab
Study Phase: Phase 2
Rare Diseases Clinical Research Network Advancing Research and Treatment for Frontotemporal Lobar Degeneration [ARTFL]: Research Projects 1 & 2
Rare Diseases Clinical Research Network Advancing Research and Treatment for Frontotemporal Lobar Degeneration [ARTFL]: Research Projects 1 & 2
Enrollment Status: Completed
Publish Date: May 21, 2021
View 9 Less Clinical Trials

39 Total Publications

Effects of Exercise and Intensive Vascular Risk Reduction on Cognitive Function in Older Adults: A Randomized Clinical Trial.
Effects of Exercise and Intensive Vascular Risk Reduction on Cognitive Function in Older Adults: A Randomized Clinical Trial.
Journal: JAMA neurology
Published: March 23, 2026
Similar Doctors
Expertise in
4
conditions
Expertise in
4
conditions
Referral may be required

Dallas County Hospital District

5200 Harry Hines Blvd, 
Dallas, TX 
 (6.5 miles away)
214-590-8000
Languages Spoken:
English
See accepted insurances

Joseph Berger is a Geriatrics provider practicing medicine in Dallas, Texas. Dr. Berger is highly rated in 4 conditions, according to our data. His clinical expertise encompasses Progressive Multifocal Leukoencephalopathy, Tabes Dorsalis, End-Stage Renal Disease (ESRD), and Encephalitis Lethargica.

Expertise in
22
conditions
Dr. Jennifer O. Attmore
Geriatrics | Internal Medicine
Expertise in
22
conditions
Dr. Jennifer O. Attmore
Geriatrics | Internal Medicine
Referral may be required

Texas Health Internal Medicine Residency Clinic

7000 W Plano Pkwy., Suite 250, 
Plano, TX 
 (11.6 miles away)
972-981-7255
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jennifer Attmore is a primary care provider, practicing in Geriatrics and Internal Medicine in Plano, Texas. Dr. Attmore is highly rated in 22 conditions, according to our data. Her clinical expertise encompasses Sitosterolemia, High Cholesterol, Vitamin D Deficiency, and Familial Hypertension.

Expertise in
29
conditions
Dr. Paul B. Anthony
Geriatrics | Internal Medicine
Expertise in
29
conditions
Dr. Paul B. Anthony
Geriatrics | Internal Medicine
Referral may be required
Before you request

Texas Health Adult Care

2100 Hedgcoxe Road, Suite 100, 
Plano, TX 
 (14.3 miles away)
972-801-3600
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Paul Anthony is a primary care provider, practicing in Geriatrics and Internal Medicine in Plano, Texas. Dr. Anthony is highly rated in 29 conditions, according to our data. His clinical expertise encompasses High Cholesterol, Infant Hyperglycemia, Sitosterolemia, and Multiple Carboxylase Deficiency. Dr. Anthony is currently accepting new patients.

Frequently Asked Questions about Dr. Diana R. Kerwin

How do I make an appointment with Dr. Diana R. Kerwin?

You can book an appointment with Dr. Diana R. Kerwin by calling their office at 972-433-9100. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Diana R. Kerwin a top-rated expert for Dementia?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Diana R. Kerwin is classified as an Distinguished expert for Dementia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Diana R. Kerwin specialize in?

While Dr. Diana R. Kerwin is a Geriatrics, they have specific expertise in Dementia, Alzheimer's Disease, and Frontotemporal Dementia. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Geriatrics.

Does Dr. Diana R. Kerwin participate in research or clinical trials?

Yes. Dr. Diana R. Kerwin has published 39 articles and abstracts on conditions like Dementia. You can view a list of Dr. Diana R. Kerwin's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Diana R. Kerwin accept my insurance?

Dr. Diana R. Kerwin accepts most major insurance plans, including Health Care Services Corporation and Humana. We recommend calling the office directly at 972-433-9100 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kerwin's expertise for a condition
ConditionClose
    View All 14 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile